I. Introduction to Acral Lentiginous Melanoma (ALM)

Acral Lentiginous Melanoma (ALM) is a distinct and aggressive subtype of melanoma that arises on the acral skin—specifically the palms of the hands, soles of the feet, and beneath the nail beds (subungual region). Unlike more common cutaneous melanomas, ALM is not strongly linked to ultraviolet (UV) radiation exposure. Its defining characteristic is a lentiginous (flat, spreading) growth pattern of atypical melanocytes along the dermo-epidermal junction in its early phases, which can later become invasive. This malignancy often presents as an irregularly pigmented macule or patch that can be easily mistaken for a benign lesion, leading to delays in diagnosis. The term nevo acrale is sometimes used in medical literature, particularly in Romance languages, to refer broadly to a nevus (mole) located on acral sites. It is crucial to understand that while a nevo acrale benigno (a benign acral nevus) is common and harmless, ALM represents the progression to a nevo acrale maligno (a malignant acral nevus).

In terms of prevalence and demographics, ALM exhibits significant ethnic and geographic variation. It is the most common form of melanoma in people with darker skin phototypes (Fitzpatrick V-VI), including individuals of African, Asian, and Hispanic descent. For instance, in Hong Kong, melanoma is relatively rare compared to Western populations, but when it does occur, ALM constitutes a substantial proportion of cases. Data from the Hong Kong Cancer Registry indicates that among the registered melanoma cases, acral and mucosal subtypes are overrepresented, highlighting the importance of awareness in Asian populations. Globally, ALM accounts for only 2-3% of all melanomas in Caucasian populations but 29-72% in Asian populations and 60-70% in Black populations. This disparity underscores that ALM is an equal-opportunity disease in terms of sun exposure but is heavily influenced by genetic factors.

Why is ALM different from other melanomas? The primary distinction lies in its etiology and clinical behavior. Common melanomas (e.g., superficial spreading, nodular) are predominantly driven by cumulative UV damage, often occurring on intermittently sun-exposed areas. ALM, conversely, develops on body sites shielded from the sun, suggesting a different oncogenic pathway. Its molecular profile is distinct, with lower frequencies of BRAF V600E mutations and higher incidences of mutations in genes like KIT, NRAS, and copy number alterations. Furthermore, ALM is notorious for its delayed diagnosis. Lesions on the soles or under nails are often overlooked or attributed to trauma, fungal infection, or a benign nevo acrale. This diagnostic lag often results in the tumor being discovered at a more advanced, thicker stage, which correlates with a poorer prognosis compared to other melanoma subtypes diagnosed at a similar thickness.

II. Understanding the Causes and Risk Factors

The precise etiology of Acral Lentiginous Melanoma remains an area of active research, but it is understood to arise from a complex interplay of genetic predisposition and somatic mutations, with minimal contribution from traditional environmental factors like UV radiation.

A. Genetic Predisposition

Unlike UV-induced melanomas, ALM shows a strong genetic component. While most cases are sporadic, certain familial syndromes and genetic markers increase risk. Mutations in the CDKN2A gene, known for its role in familial melanoma, are less common in ALM. Instead, research points to alterations in pathways regulating cell cycle and growth. A key player is the receptor tyrosine kinase KIT. Activating mutations or amplifications in the KIT gene are found in approximately 10-20% of ALM cases, making it a critical target for therapy. Furthermore, whole-genome sequencing studies have revealed a higher burden of structural variants and focal amplifications (e.g., in CCND1, TERT, GAB2) in ALM compared to sun-exposed melanomas. These genetic differences explain its unique biology and resistance to therapies effective for other subtypes. The risk is also elevated in individuals with a high number of acral nevi. Distinguishing a benign nevo acrale benigno from an early nevo acrale maligno requires careful dermatoscopic examination and, often, histopathological confirmation.

B. Environmental Factors

The role of environmental factors in ALM is subtle and not related to sunbathing or tanning bed use. Some studies have explored potential links to chemical exposures or chronic inflammation, but evidence is inconclusive. One theory suggests that repetitive mechanical stress or trauma might act as a promoting factor, though this is not a direct cause. The primary environmental lesson is the absence of a UV link, which means public health messages focused solely on sun protection are insufficient for preventing ALM. Awareness must be directed towards self-examination of all skin surfaces, including hidden acral sites.

C. Footwear and Trauma: Dispelling Myths

A persistent myth suggests that tight-fitting shoes or chronic trauma cause ALM on the feet. While such factors can cause calluses, bruises, or ulcers that may mimic or obscure ALM, there is no robust epidemiological evidence proving they are causative. The association is likely coincidental and confounded by detection bias: a lesion subjected to pressure becomes symptomatic (e.g., painful, bleeding), prompting medical attention. It is vital to dispel this myth to avoid misattribution. A painful, non-healing "callus" or "blood blister" on the foot, especially in an adult, should be examined for ALM, not simply dismissed as a consequence of footwear. This underscores the importance of not ignoring any new, changing, or symptomatic pigmentation on acral skin, regardless of perceived cause.

III. Recognizing the Signs and Symptoms

Early recognition of ALM is challenging but paramount for improving outcomes. The lesions are often asymptomatic in early stages, and their locations are not routinely checked.

A. Location: Palms, Soles, and Nail Beds

ALM has a predilection for specific acral sites:

• Soles: The most common location, particularly the weight-bearing areas like the heel, ball of the foot, and lateral borders.
• Palms: Less common than sole involvement.
• Nail Beds (Subungual): Presents as a longitudinal melanonychia—a brown or black streak running from the nail matrix to the tip. Involvement of the periungual skin (Hutchinson's sign) is a critical warning sign of malignancy.

Importantly, these are also sites where benign entities like lentigines, nevo acrale benigno, and fungal stains are common, making clinical differentiation difficult.

B. The ABCDEs of Melanoma in ALM

The classic ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution) applies but requires adaptation for acral sites. For ALM, Evolution (change) is the single most important criterion. Other key features include:

• Color: A mix of tan, brown, black, and sometimes red, white, or blue. The pigmentation is often uneven and may have a "furry" or smudged appearance.
• Border: Irregular, jagged, or notched edges. The lesion may appear to "bleed" pigment into the surrounding skin.
• Diameter: While often large at diagnosis, early ALM can be small. Do not disregard a small but changing lesion.
• Additional Signs for ALM (the "CUBED" mnemonic): Color variability, Uncertainty in diagnosis, Bleeding or ulceration, Enlargement, and Delay in healing (any lesion >3 months).

A subungual ALM may present as a widening, darkening streak, nail dystrophy, or nail plate splitting.

C. Case Studies and Visual Examples

Consider a 55-year-old Chinese patient in Hong Kong presenting with a 2-year history of a slowly enlarging, irregularly pigmented patch on the sole. It was initially thought to be a stain or a benign nevo acrale. Dermatoscopy revealed a parallel ridge pattern (specific for melanoma on volar skin) with irregular brown-black lines and dots. Biopsy confirmed early invasive ALM. Another case involved a 40-year-old individual with a new, rapidly expanding black streak on the thumbnail with associated periungual pigmentation (Hutchinson's sign). This was not a benign melanonychia but a nevo acrale maligno requiring prompt intervention. These examples highlight that visual familiarity, often aided by dermoscopy, is critical for suspicion.

IV. Diagnosis and Staging of ALM

Timely and accurate diagnosis is the cornerstone of managing ALM. A high index of suspicion is needed for any atypical acral pigmentation.

A. Biopsy Techniques

The gold standard for diagnosis is an excisional biopsy with narrow margins, removing the entire lesion if possible. This allows for accurate measurement of tumor thickness (Breslow depth), the most critical prognostic factor. For large lesions on functionally sensitive areas (e.g., heel), an incisional or punch biopsy of the most clinically suspicious (thickest, darkest) area may be performed initially. Pathological examination will assess for the characteristic lentiginous proliferation of atypical melanocytes and degree of invasion. Immunohistochemical stains (e.g., SOX10, Melan-A, HMB-45) are used to confirm melanocytic origin. The pathologist's report must differentiate a nevo acrale maligno from its benign simulants, such as an acral nevus with atypical features.

B. Sentinel Lymph Node Biopsy

For invasive ALM with a Breslow thickness >0.8 mm (or >0.7 mm in some guidelines), or with other high-risk features (ulceration, high mitotic rate), a Sentinel Lymph Node Biopsy (SLNB) is recommended. This procedure maps the lymphatic drainage from the primary tumor site to the first (sentinel) lymph node(s) in the regional basin. The node is examined for micrometastases. A positive SLNB is the most important prognostic factor for recurrence and upstages the disease, guiding further management decisions. In Hong Kong, this procedure is standard of care for eligible melanoma patients in major cancer centers.

C. Staging System Explained

ALM is staged using the American Joint Committee on Cancer (AJCC) 8th Edition TNM system, common to all melanomas. Staging incorporates:

• T (Tumor): Based on Breslow thickness and ulceration.
• N (Nodes): Number and characteristics of involved regional lymph nodes.
• M (Metastasis): Presence and location of distant metastases.

These are combined into stages 0 to IV. Early-stage (0-I) disease is localized. Stage II involves thicker tumors without nodal spread. Stage III indicates regional nodal or in-transit metastasis. Stage IV signifies distant metastasis (e.g., to lungs, liver, brain). Prognosis declines sharply with advancing stage. For example, the 5-year survival for localized ALM (Stage I/II) can be over 80%, but drops to 20-40% for Stage IV disease.

V. Treatment Options for ALM

Treatment for ALM is multidisciplinary and depends heavily on the stage at diagnosis. The landscape has evolved significantly with the advent of targeted and immunotherapies.

A. Surgical Excision

Surgery remains the primary curative treatment for localized ALM. After diagnostic biopsy, wide local excision is performed. The recommended surgical margins are:

Breslow Thickness	Excision Margin
In situ	0.5 - 1.0 cm
≤ 1.0 mm	1.0 cm
1.01 - 2.0 mm	1.0 - 2.0 cm
>2.0 mm	2.0 cm

For subungual ALM, this often requires partial or complete amputation of the digit. The goal is to achieve clear histological margins while preserving as much function as possible. In cases with positive sentinel nodes, a completion lymph node dissection may be considered, though its survival benefit is debated.

B. Targeted Therapy and Immunotherapy

For advanced (unresectable Stage III or Stage IV) ALM, systemic therapy is the mainstay. Treatment selection is guided by molecular testing of the tumor.

• Targeted Therapy: For tumors harboring KIT mutations (approx. 15-20%), tyrosine kinase inhibitors like imatinib, nilotinib, or sunitinib may be used, though response rates are variable. Drugs targeting NRAS or other pathways are under investigation.
• Immunotherapy: This has revolutionized melanoma treatment. Checkpoint inhibitors such as anti-PD-1 agents (pembrolizumab, nivolumab) and anti-CTLA-4 (ipilimumab) work by unleashing the body's immune system against cancer cells. They are effective regardless of mutation status and are now standard first-line options for advanced ALM, showing durable responses in a subset of patients.

Adjuvant immunotherapy (post-surgery) is also standard for high-risk Stage II/III disease to reduce recurrence risk.

C. Clinical Trials and Emerging Treatments

Given the relative rarity and unique genetics of ALM, participation in clinical trials is highly encouraged. Research is exploring:

• Novel immunotherapy combinations and biomarkers for response prediction.
• Adoptive cell therapies like Tumor-Infiltrating Lymphocytes (TIL).
• Oncolytic viruses (e.g., talimogene laherparepvec).
• More potent and selective KIT inhibitors.
• Intralesional therapies for in-transit metastases.

Patients in Hong Kong have access to international and regional trials through major oncology hospitals, offering hope for newer, more effective treatments.

VI. Living with ALM: Management and Support

A diagnosis of ALM initiates a lifelong journey of surveillance and adaptation. Comprehensive care extends beyond physical treatment.

A. Follow-up Care and Monitoring

Regular follow-up is crucial to detect recurrence or new primary melanomas early. The schedule is typically:

• Every 3-6 months for the first 2-3 years.
• Every 6-12 months for years 3-5.
• Annually thereafter.

Visits include a full skin and lymph node examination. Patients are taught thorough self-examination of their skin, including acral sites. Imaging (CT, PET-CT, MRI) may be used periodically for higher-stage disease. Any new lesion, especially one resembling a nevo acrale, should be promptly evaluated to rule out a new primary or metastasis.

B. Support Groups and Resources

Emotional and informational support is vital. Patients can benefit from connecting with others who share their experience. Resources include:

• Local Support: Hospital-based oncology social workers and patient support groups in Hong Kong, such as those affiliated with the Hong Kong Anti-Cancer Society or individual hospitals.
• International Organizations: The Melanoma Research Foundation (MRF) and AIM at Melanoma provide extensive online resources, webinars, and community forums.
• Genetic Counseling: May be offered, especially for younger patients or those with a family history.

C. Psychological Impact and Coping Strategies

A cancer diagnosis, especially of a potentially aggressive type like ALM, can cause significant anxiety, depression, and fear of recurrence. The location of the disease (e.g., on the foot) may also impact body image and mobility. Effective coping strategies include:

• Psycho-oncology Services: Seeking professional counseling or therapy to manage anxiety and develop coping mechanisms.
• Mindfulness and Stress Reduction: Practices like meditation, yoga, or tai chi can help manage stress.
• Open Communication: Maintaining honest dialogue with family, friends, and the medical team.
• Focus on Controllables: Empowering oneself through education about the disease, adhering to follow-up schedules, and maintaining a healthy lifestyle.

Understanding that a nevo acrale benigno and a nevo acrale maligno are on a spectrum of disease, but with vastly different outcomes, reinforces the importance of vigilance and proactive healthcare engagement for life.